Display options
Cite
Bruno, R., Hille, D., Riva, A., Vivier, N., ten Bokkel Huinnink, W. W., Van Oosterom, A. T., ... & Sheiner, L. B. (1998). Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. Journal of clinical oncology, 16(1), 187-196.
Bruno, Rene, et al. "Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer." Journal of clinical oncology 16.1 (1998): 187-196.
Copy Download .nbib Format: MLA
Share it on
Full text links
View full text

R Bruno, D Hille, A Riva, N Vivier… - Journal of clinical …, 1998 - Citeseer

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Build and Broaden 3.0 AND Program Evaluation

Bruno, Hille, Riva

GSID: cN3u3FPD-8gJ

Excerpt

Conclusion: First-course docetaxel PK is a predictor of first-course hematologic toxicity, but also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes have a 27% reduction in docetaxel CL and are at a higher risk of toxicity. A starting dose of 75 mg/m 2 is currently being evaluated in this population. Prospective implementation of largescale population PK/PD evaluation is feasible in early drug development and this approach generates clinically relevant findings.

Similar articles

Cited by